|
Advancing Hemoglobinopathy Care: Innovative BCL11A Inhibition for Sustained Fetal Hemoglobin Production
Advancing Hemoglobinopathy Care: Innovative BCL11A Inhibition for Sustained Fetal Hemoglobin Production
Background
Hemoglobinopathies, including sickle cell anemia and β-thalassemias, are genetic disorders caused by mutations that impair the production or structure of of β-globin chains in hemoglobin. These conditions result in patients...
Published: 3/25/2026
|
Updated: 12/5/2025
|
Inventor(s): Daniel Bauer, Yuxuan Wu, Jing Zeng, Scot Wolfe, Mehmet Bolukbasi, Benjamin Roscoe, Pengpeng Liu, Luk.Kevin
Keywords(s): Sickle Cell Anemia
Category(s): Technology Classifications > Invention Type > Therapeutics > Gene Therapy, Technology Classifications > Invention Type > Therapeutics, Technology Classifications > Disease Area > Hematology/Oncology, Technology Classifications > Invention Type > Therapeutics > Gene Editing
|
|
Targeting ZNF410 for fetal hemoglobin induction in beta-hemoglobinopathies
Targeting ZNF410 for fetal hemoglobin induction in beta-hemoglobinopathies
Background
β-hemoglobinopathies, such as sickle cell disease and β-thalassemias, are genetic disorders characterized by defective hemoglobin production, resulting in anemia and impaired oxygen delivery. These conditions affect millions worldwide, posing significant...
Published: 3/26/2026
|
Updated: 11/29/2025
|
Inventor(s): Daniel Bauer, Divya Vinjamur
Keywords(s):
Category(s): Technology Classifications > Disease Area > Hematology/Oncology, Technology Classifications > Invention Type > Novel Targets
|
|
Enhanced BCL11A RNP / CRISPR delivery & editing using a 3xNLS-Cas9
Advancing Gene Therapy for Hemoglobinopathies: Enhanced CRISPR-Cas9 with Multi-NLS Integration
Background
Sickle cell disease (SCD) and β-thalassemia are severe β-globin disorders affecting millions globally, characterized by defective adult hemoglobin that fails to transport oxygen effectively, leading to significant morbidity. Existing...
Published: 3/25/2026
|
Updated: 10/13/2025
|
Inventor(s): Daniel Bauer, Pengpeng Liu, Scot Wolfe, Yuxuan Wu, Jing Zeng
Keywords(s):
Category(s): Technology Classifications > Disease Area > Hematology, Technology Classifications > Disease Area > Rare Diseases, Technology Classifications > Invention Type > Therapeutics, Technology Classifications > Invention Type > Therapeutics > Gene Editing
|
|
Advanced CRISPR/Cas Technology for Targeted Fetal Hemoglobin Reinduction in Hemoglobinopathy Treatment
Advanced CRISPR/Cas Technology for Targeted Fetal Hemoglobin Reinduction in Hemoglobinopathy Treatment
Background
Hemoglobinopathies, such as β-thalassemias and sickle cell anemia, represent a significant unmet medical need affecting millions globally. These genetic disorders are characterized by defective or deficient production of normal β-globin,...
Published: 3/26/2026
|
Updated: 10/9/2025
|
Inventor(s): Daniel Bauer
Keywords(s):
Category(s): Technology Classifications > Disease Area > Hematology, Technology Classifications > Invention Type > Therapeutics > Gene Therapy
|
|
Hematopoietic Stem Cell Transplantation: Enhanced Engraftment without Chemotherapy for Genetic and Acquired Disorders
Hematopoietic Stem Cell Transplantation: Enhanced Engraftment without Chemotherapy for Genetic and Acquired Disorders
Background
There is a crucial unmet medical need for improved methods to treat inherited and acquired diseases via hematopoietic stem cell transplantation. Currently, patients must undergo high-dose alkylating chemotherapy as part...
Published: 3/26/2026
|
Updated: 10/9/2025
|
Inventor(s): Daniel Bauer, Vivien Schoonenberg, Sabine Studer, Sebastien Levesque
Keywords(s):
Category(s): Technology Classifications > Invention Type > Therapeutics > Cell Therapy, Technology Classifications > Invention Type > Therapeutics, Technology Classifications > Disease Area > Hematology
|
|
Therapeutic twin prime editing of hematopoietic stem cells for TINF2 dyskeratosis congenita
Therapeutic twin prime editing of hematopoietic stem cells for TINF2 dyskeratosis congenita
Background
Dyskeratosis congenita (DC) is a rare, genetic form of bone marrow (BM) failure. It is estimated that one in one million people has this condition. About 50% of the people who have DC have changes in the genes that are important in telomere maintenance,...
Published: 3/26/2026
|
Updated: 11/20/2024
|
Inventor(s): Daniel Bauer, Sebastien Levesque
Keywords(s):
Category(s): Technology Classifications > Disease Area > Rare Diseases, Technology Classifications > Disease Area > Hematology, Technology Classifications > Invention Type > Therapeutics > Gene Editing
|
|
Improving gene editing by modulating nucleotide metabolism
Improving gene editing by modulating nucleotide metabolism
Background
Currently, most treatments for genetic blood-related disorders (both non-cancerous and cancerous) aim to alleviate symptoms, manage complications, and slow disease progression, rather than completely correcting the underlying genetic defect. In some cases, patients may qualify...
Published: 3/26/2026
|
Updated: 11/20/2024
|
Inventor(s): Daniel Bauer, Sebastien Levesque
Keywords(s):
Category(s): Technology Classifications > Invention Type > Therapeutics > Gene Editing, Technology Classifications > Disease Area > Rare Diseases
|
|
Temp: Repair of ELANE therapeutic gene editing for congenital neutropenia
Therapeutic Gene Editing for Severe Congenital Neutropenia
Background
Severe congenital neutropenia (SCN) is a rare inherited disorder characterized by low absolute neutrophil counts which increases the risk of life-threatening infections. Occurrence of SCN is attributed to changes in various genes, but an estimated 50% of severe congenital...
Published: 3/26/2026
|
Updated: 4/11/2024
|
Inventor(s): Daniel Bauer, Scot Wolfe, Peter Newburger, Josias Frazão, Shuquan Rao
Keywords(s):
Category(s): Technology Classifications > Invention Type > Therapeutics, Technology Classifications > Invention Type > Therapeutics > Gene Therapy, Technology Classifications > Disease Area > Rare Diseases
|
